Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...

“ Subcutaneous methylnaltrexone, currently marketed as RELISTOR ®, is an effective and well-tolerated therapy used to alleviate OIC in advanced illness patients receiving opioids for pain,” said ...

Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 ...

Pharmacology: The use of opioid analgesics can lead to constipation due to their effect on intestinal smooth muscle and their interference with the bowel’s normal elimination function.

Man Stomach Pain Previously, it had only been available as a subcutaneous injection. Relistor (methylnaltrexone bromide; Valeant and Progenics) Tablets are now available for the treatment of ...

TARRYTOWN, N.Y., May 20, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety ...

Relistor approved for OIC Salix and Progenics announced that the Food and Drug Administration (FDA) has approved Relistor (methylnaltrexone) subcutaneous injection for the treatment of opioid-induced ...

Please provide your email address to receive an email when new articles are posted on . A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced ...

today announced the successful outcome of the Phase 3 trial to evaluate the efficacy and safety of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, ...